Korea's top export market hands you two MoCRA lists, not one
Korean cosmetics exports to the US reached USD 2.35 billion in the first nine months of 2026, up 40.6%. But MoCRA does not arrive as one set of duties. Facility registration sits with the Korean plant; everything else sits with whoever is named on the label.
MoCRA splits into two lists. The Korean manufacturing plant registers its facility with the FDA, renews biennially and names a U.S. agent. Product listing, safety substantiation, adverse event handling and the label contact are Responsible Person duties, and the Responsible Person is whoever is named on the label as manufacturer, packer or distributor. In an OEM or ODM arrangement that is usually the US brand owner or importer, not the factory. FDA counted 16,398 active facility registrations and 1,298,361 active product listings as of 30 June 2026, up from 14,299 and 992,907 on 6 January — roughly 300,000 listings added in half a year.
The year the US became number one is the year the paperwork settled
Korea's Ministry of Food and Drug Safety reported provisional figures on 2 October 2026: exports for January to September reached USD 11.1 billion, up 31.1%. The US accounted for USD 2.35 billion, up 40.6%, a 21.1% share and first place. China came to USD 1.58 billion on 0.4% growth, a 14.2% share — down from 46.7% in 2022.
What moved with the volume is a registration regime. Since MoCRA took effect in 2023, the FDA has had facility registration, product listing, adverse event reporting, registration suspension and mandatory recall authority over cosmetics. Holding onto that export number now depends on filings that keep cycling.
This is where buyers and Korean manufacturers most often talk past each other. MoCRA is not one bundle of duties. It is two bundles — one on the plant, one on the label.
The plant's list and the label's list are different
Facility registration belongs to the manufacturer. A foreign plant producing cosmetics for the US market registers with the FDA, renews every two years, registers a new facility within 60 days of starting operations, and names a U.S. agent at registration.
Everything else belongs to the Responsible Person, defined as whoever appears on the label as manufacturer, packer or distributor. The label is what decides it, not the production arrangement behind it.
| Duty | Whose | Timing |
|---|---|---|
| Facility registration | Manufacturer (Korean plant) | Biennial renewal; new facility within 60 days |
| U.S. agent designation | Manufacturer | At registration |
| Product listing | Responsible Person | Annual update; new product within 120 days |
| Holding safety substantiation | Responsible Person | Ongoing |
| Adverse event intake and reporting | Responsible Person | Serious events within 15 business days |
| Domestic US contact on label | Responsible Person | Since 29 December 2024 |
In an ODM or OEM deal that table splits across two companies. If the Korean plant manufactures and the product sells under a US brand, the plant registers and the US company carries the rest. If a Korean brand exports under its own name, it carries both columns. That choice decides who prepares which documents and who pays, so it belongs in the discussion before the quotation does.
There are already 1.29 million listings
The FDA counted 16,398 active facility registrations and 1,298,361 active product listings as of 30 June 2026. On 6 January the figures were 14,299 and 992,907, so roughly 300,000 listings were added in six months.
Two things follow. Registration is no longer a barrier to entry — with 1.29 million listings on file, having one is not a differentiator. And the FDA can now read ingredient composition product by product, because listings include ingredients, so a composition that raises no question in Korea becomes visible in a US list.
The burden is in the cadence rather than the first filing. Listings update annually and a new product must be listed within 120 days of going to market, which makes the clock recurring work for a brand shipping new SKUs and bundle sets through the year. Demand signals for candidate products update daily in today's ingredient signals, but for a US-bound range the listing calendar sits next to them.
One mascara removes the exemption from everything
The small business exemption lifts facility registration, product listing and GMP duties for a business whose gross annual sales, averaged over the previous three years, are under USD 1 million. That is real relief for a brand just starting to export — except that the four carve-outs from it are unusually common in Korean ranges.
| Carved out of the exemption | Typical Korean SKU |
|---|---|
| Regular contact with eye mucous membrane | Mascara, eyeliner, lash adhesive |
| Alters appearance over 24 hours | Brow tint, lash dye, gel and extension nails |
| Injected | Not applicable (outside cosmetics) |
| Internal use | Oral inner-beauty products |
And then the part that matters: carrying even one such product removes the exemption from the business entirely, for every product it sells. Ten skincare items plus one eyeliner means all eleven need registration and listing. When you assemble a US range, one SKU does not weigh the same as the others.
Sunscreen is a separate case. In the US, sunscreen is regulated as an OTC drug rather than a cosmetic, so it follows drug rules instead of MoCRA. That is also why Korean sunscreen formulas rarely travel as they are, and it deserves its own post.
Three rules are still missing
Three of the rules MoCRA set in motion remain unissued into 2026. There is no draft guidance on the GMP regulation, the fragrance allergen labelling rule has not been published, and the talc-asbestos test method proposal was withdrawn on 28 November 2025 with a revised proposal expected on uncertain timing.
Fragrance allergen labelling is the one that forces a reprint. Once it is settled which allergens must be declared above which thresholds, ingredient panels get longer, and the smaller the container the more the design has to be reworked. Committing a year of label tooling or print volume now can mean paying for it twice.
The FDA also opened a public cosmetics adverse event dashboard on 12 September 2025. Serious adverse events are reportable within 15 business days and records are kept for three to six years, and those outcomes now accumulate as public data. Registration was the start of the record, not the end of the work.
In short
- Korean cosmetics exports to the US, January to September 2026: USD 2.35 billion, up 40.6%, a 21.1% share — China is now USD 1.58 billion, up 0.4%, 14.2%
- MoCRA splits in two: facility registration and U.S. agent sit with the Korean plant; product listing, safety substantiation, adverse events and the label contact sit with whoever is named on the label
- FDA data as of 30 June 2026: 16,398 active facilities and 1,298,361 active product listings — registration is no longer a differentiator
- The small business exemption (under USD 1 million averaged over three years) disappears entirely if the range carries a single mascara, eyeliner or brow tint
- GMP, fragrance allergen labelling and the talc test method are all still open — do not commit long label print runs
- Sunscreen is an OTC drug in the US, not a cosmetic, so MoCRA is not the rule that applies to it
If you are assembling a US-bound range, the product planner returns per-SKU cost estimates and a sample brief within a day.
*Sources: US FDA, "Registration & Listing of Cosmetic Product Facilities and Products" — biennial renewal, Cosmetics Direct submission, 16,398 active facility registrations and 1,298,361 active product listings as of 30 June 2026. Foley & Lardner, "How MoCRA Is Reshaping FDA Oversight of Cosmetics in 2026" (March 2026) — 14,299 facilities and 992,907 listings as of 6 January 2026; GMP and fragrance allergen rules outstanding; talc test method proposal withdrawn 28 November 2025; FAERS public cosmetics dashboard launched 12 September 2025. Registrar Corp, "MoCRA Exemptions" — small business threshold (under USD 1 million averaged over three years) and the four carved-out product groups. Biorius, "MoCRA Cosmetics" — labelling compliance 29 December 2024 (professional use 29 December 2023), new facility 60 days, new product listing 120 days, serious adverse events within 15 days, records kept three to six years. Export figures from Korea's Ministry of Food and Drug Safety provisional release of 2 October 2026 (January–September 2026, USD 11.1 billion total, up 31.1%). Regulatory status checked 4 October 2026; pending rules may change. This is not legal advice — confirm filings with a qualified specialist.*
Questions people ask
The facility registration, yes. A foreign plant making cosmetics for the US market registers with the FDA, renews every two years, and registers a new facility within 60 days of starting operations, naming a U.S. agent at the time of registration. Product listing, safety substantiation and adverse event reporting are separate — they belong to the Responsible Person. Since the Responsible Person needs the facility registration number to file a listing, the practical flow is that the plant registers and passes its number to the brand.
Whoever is named on the product label as the manufacturer, packer or distributor. The label decides it, not who did the manufacturing. If a Korean ODM makes the product and it sells under a US brand name, that US company is the Responsible Person. If a Korean brand exports under its own name, the Korean entity is. Either way the label has to carry a domestic US address, phone number or electronic contact for adverse event reports, which means setting up a receiving channel in the US.
Yes — averaged over the previous three years, annual gross sales under USD 1 million exempt a business from facility registration, product listing and GMP duties. Four product groups are carved out of that exemption: products that regularly contact the mucous membrane of the eye (mascara, eyeliner, lash adhesive), injected products, products for internal use, and products that alter appearance for more than 24 hours (brow and lash dye, nail extensions). Carrying even one such product removes the exemption from the whole business.
MoCRA requires the Responsible Person to hold adequate substantiation that the product is safe — tests, studies or other expert-accepted evidence. It is a holding requirement, not a submission, and there is no prescribed format as there is for a European CPSR, so in practice an existing CPSR or safety assessment often serves. The underlying data usually sits with the manufacturer, so the contract should state that the Responsible Person can access and rely on it.
Three rules are still outstanding. The GMP regulation has no draft guidance yet, the fragrance allergen labelling rule has not been issued, and the talc-asbestos test method proposal was withdrawn on 28 November 2025 with a revised proposal expected. Fragrance allergen labelling is the one that forces a reprint, so committing to a long label print run now can mean paying for it twice.